BACKGROUND: The growing numbers of survivors of innovative cancer treatments, such as hematopoietic stem cell transplantation (HSCT), often report subsequent cognitive difficulties. The objective of this study was to evaluate and compare neurocognitive changes in patients with chronic myelogenous leukemia (CML) or primary myelodysplastic syndrome (MDS) after allogeneic HSCT or other therapies. METHODS: In this prospective cohort study, serial evaluations of attention, concentration, memory, mood, and quality of life were used in a consecutive sample of 106 eligible patients who had CML (n = 91) or MDS (n = 15) at enrollment and then 12 months and 18 months after HSCT or other therapy. RESULTS: The 3 evaluations at enrollment, 12 months, and 18 months were completed by 98%, 95%, and 89% of surviving participants, respectively. Among all patients, there was significant improvement in memory over 18 months. For example, the 45 patients who underwent HSCT (42 patients with CML and 3 patients with MDS) compared favorably with the patients who received other treatment on most measures of neuropsychological function, except they had improved mental health (P = .034), worse physical function (P = .049), and more difficulty with coordination and fine motor speed bilaterally (dominant hand, P = .005; nondominant hand, P = .0019). Patients with CML overall had improved phonemic fluency (P = .014). CONCLUSIONS: The current study indicated that time and diagnosis may be important factors when assessing neurocognitive and other changes. Complaints regarding "chemobrain" after HSCT merit further study, because deficits actually may predate the initiation of treatment and subsequently may improve. The study results could reassure prospective HSCT recipients, because HSCT compared favorably with other treatments when mental status side effects were considered. 2009 American Cancer Society.
BACKGROUND: The growing numbers of survivors of innovative cancer treatments, such as hematopoietic stem cell transplantation (HSCT), often report subsequent cognitive difficulties. The objective of this study was to evaluate and compare neurocognitive changes in patients with chronic myelogenous leukemia (CML) or primary myelodysplastic syndrome (MDS) after allogeneic HSCT or other therapies. METHODS: In this prospective cohort study, serial evaluations of attention, concentration, memory, mood, and quality of life were used in a consecutive sample of 106 eligible patients who had CML (n = 91) or MDS (n = 15) at enrollment and then 12 months and 18 months after HSCT or other therapy. RESULTS: The 3 evaluations at enrollment, 12 months, and 18 months were completed by 98%, 95%, and 89% of surviving participants, respectively. Among all patients, there was significant improvement in memory over 18 months. For example, the 45 patients who underwent HSCT (42 patients with CML and 3 patients with MDS) compared favorably with the patients who received other treatment on most measures of neuropsychological function, except they had improved mental health (P = .034), worse physical function (P = .049), and more difficulty with coordination and fine motor speed bilaterally (dominant hand, P = .005; nondominant hand, P = .0019). Patients with CML overall had improved phonemic fluency (P = .014). CONCLUSIONS: The current study indicated that time and diagnosis may be important factors when assessing neurocognitive and other changes. Complaints regarding "chemobrain" after HSCT merit further study, because deficits actually may predate the initiation of treatment and subsequently may improve. The study results could reassure prospective HSCT recipients, because HSCT compared favorably with other treatments when mental status side effects were considered. 2009 American Cancer Society.
Authors: Helena Harder; Hugo J Duivenvoorden; Arthur R van Gool; Jan J Cornelissen; Martin J van den Bent Journal: J Clin Exp Neuropsychol Date: 2006-04 Impact factor: 2.475
Authors: J Douglas Rizzo; John R Wingard; Andre Tichelli; Stephanie J Lee; Maria Teresa Van Lint; Linda J Burns; Stella M Davies; James L M Ferrara; Gérard Socié Journal: Biol Blood Marrow Transplant Date: 2006-02 Impact factor: 5.742
Authors: F Schulz-Kindermann; A Mehnert; A Scherwath; L Schirmer; B Schleimer; A R Zander; U Koch Journal: Bone Marrow Transplant Date: 2007-04-09 Impact factor: 5.483
Authors: James C Root; Claudine Campbell; Xiomara Rocha-Cadman; Nicole Kasven-Gonzalez; Molly Maloy; Jessica Flynn; Sean M Devlin; Ann A Jakubowski Journal: Biol Blood Marrow Transplant Date: 2020-05-21 Impact factor: 5.742
Authors: Samantha J Mayo; Hans A Messner; Sean B Rourke; Doris Howell; J Charles Victor; Jeffrey H Lipton; J Kuruvilla; Vikas Gutpa; Dennis Dong Hwan Kim; Fotios V Michelis; Kelly Metcalfe Journal: Bone Marrow Transplant Date: 2019-11-19 Impact factor: 5.483
Authors: Grace Chang; Mary-Ellen Meadows; Jennifer A Jones; Joseph H Antin; E John Orav Journal: Am J Drug Alcohol Abuse Date: 2010-01 Impact factor: 3.829
Authors: Karen L Syrjala; Samantha B Artherholt; Brenda F Kurland; Shelby L Langer; Sari Roth-Roemer; JoAnn Broeckel Elrod; Sureyya Dikmen Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala Journal: Biol Blood Marrow Transplant Date: 2016-09-19 Impact factor: 5.742
Authors: D D Correa; J C Root; R Baser; D Moore; K K Peck; E Lis; T B Shore; H T Thaler; A Jakubowski; N Relkin Journal: Brain Imaging Behav Date: 2013-12 Impact factor: 3.978
Authors: D D Correa; Y Wang; J D West; K K Peck; J C Root; R E Baser; H T Thaler; T B Shore; A Jakubowski; A J Saykin; N Relkin Journal: Brain Imaging Behav Date: 2016-06 Impact factor: 3.978